Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR-Reference-Cited by-同舟云学术

Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR

Published:2021-05-02 Issue:6 Volume:112 Page:2371-2380
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Ariyasu Ryo¹²,Uchibori Ken¹²,Sasaki Takaaki³^ORCID,Tsukahara Mika¹,Kiyotani Kazuma⁴^ORCID,Yoshida Ryohei³,Ono Yusuke⁵,Kitazono Satoru²,Ninomiya Hironori⁶,Ishikawa Yuichi⁶^ORCID,Mizukami Yusuke⁵^ORCID,Yanagitani Noriko²,Fujita Naoya¹^ORCID,Nishio Makoto²^ORCID,Katayama Ryohei¹^ORCID

Affiliation:

1. Cancer Chemotherapy Center Japanese Foundation for Cancer Research Tokyo Japan

2. Department of Thoracic Medical Oncology The Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan

3. Respiratory Center Asahikawa Medical University Hospital Asahikawa Japan

4. Immunopharmacogenomics Group Cancer Precision Medicine Center Japanese Foundation for Cancer Research Tokyo Japan

5. Institute of Biomedical Research Sapporo Higashi Tokushukai Hospital Sapporo Japan

6. Division of Pathology Cancer Institute Japanese Foundation for Cancer Research Tokyo Japan

Funder

Japan Agency for Medical Research and Development

Uehara Memorial Foundation

Nippon Foundation

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14879

Reference33 articles.

1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

3. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

4. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

5. EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Custom-Designed Probes for the Accurate Determination of Epidermal Growth Factor Receptor Mutations and Their Allelic Configuration;Analytical Chemistry;2024-06-04

2. CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma;Communications Biology;2024-05-28

3. Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?;Journal of Clinical Medicine;2023-02-10

4. Current treatment of non-small cells lung cancer with EGFR mutation: first-line and management upon progression;Revisiones en Cáncer;2023

5. EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy;Investigational New Drugs;2022-09-24